SMAD4 and metastatic neoplasm: Iacobuzio-Donahue et al. previously observed that locally advanced PDAC without metastatic disease uncommonly showed loss of SMAD4 (22%) as compared with carcinomas with extensive metastatic burden, where the rates of SMAD4 alteration approached 75% [25].